Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

THC Biomed Intl Ltd C.THC

Alternate Symbol(s):  THCBF

THC Biomed Intl Ltd. is a Canada-based cannabis producer. The Company’s principal business is the production and sale of cannabis through THC BioMed Ltd., which is a small batch Licensed Producer as regulated by the Cannabis Act which regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company’s biological assets consist of cannabis plants (mother plants and clones for growth); resin; oil; harvested marijuana flowers prior to completion of the drying, grading and testing processes; and edible concentrate. The Company operates in a single reportable segment being the cultivation and sale of cannabis. Its subsidiaries include THC BioMed Ltd., Clone Shipper Ltd., THC BioMed Victoria Falls Ltd., THC2GO Dispensaries Ltd. (THC2GO), and THC BioMed Lesotho Ltd. (THC Lesotho). Clone Shipper Ltd. owns all rights to the Clone Shipper product used to transport live plants.


CSE:THC - Post by User

Post by ART535455on Sep 08, 2020 4:48pm
152 Views
Post# 31522340

THC DOES NOT HAVE TO MANY PROBLEMS.

THC DOES NOT HAVE TO MANY PROBLEMS.

Aurora names new CEO, expects up to $1.8B in goodwill impairment charges

Published

 

 1 minute read

 

EDMONTON — Aurora Cannabis Inc. promoted Miguel Martin to chief executive and warned that it expects to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of its 2020 financial year.

Martin was chief executive of U.S. CBD company Reliva when Aurora acquired it earlier this year and became chief commercial officer at Aurora in July.

Michael Singer, who had been interim CEO since the retirement of Terry Booth in February, will remain executive chairman.

In its financial update, Aurora says net revenue in its fourth quarter is expected to be between $70 million and $72 million, compared with $75.5 million in its third quarter.

 

Cannabis net revenue is expected to be between $66 million and $68 million, compared with $69.6 million in the third quarter.

Aurora plans to release its full results for its fourth quarter and financial year ended June 30 after the close of markets on Sept. 22.

This report by The Canadian Press was first published Sept. 8, 2020.

Companies in this story: (TSX:ACB)

 


<< Previous
Bullboard Posts
Next >>